Share Name Share Symbol Market Type Share ISIN Share Description
Rua Life Sciences Plc LSE:RUA London Ordinary Share GB0033360586 ORD 5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 40.00 38.00 42.00 40.00 40.00 40.00 92,874 01:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 1.5 -1.6 -8.2 - 9

RUA Life Sciences PLC Update re Notice of Annual General Meeting

13/08/2021 2:43pm

UK Regulatory (RNS & others)

Rua Life Sciences (LSE:RUA)
Historical Stock Chart

From May 2021 to May 2022

Click Here for more Rua Life Sciences Charts.


RNS Number : 6468I

RUA Life Sciences PLC

13 August 2021

13 August 2021

RUA Life Sciences plc

("RUA" or the "Company")

2021 Notice of Annual General Meeting - Correction

RUA Life Sciences (AIM:RUA) , the holding company of a group of medical device businesses focused on the exploitation of the world's leading long-term implantable biostable polymer (Elast-Eon(TM) ), announces that resolution numbered 7 ("Resolution 7") set out in its Notice of 2021 Annual General Meeting (the "Notice") to be held on Tuesday 31 August 2021 ("AGM") contained certain typographical errors. Resolution 7 refers to proposed authorities to allot (or grant rights over) new ordinary shares in the capital of RUA pursuant to either an open offer or a rights issue. As set out in the explanatory notes to the Notice, the intention is that such authorities comply with the Investment Association's guidelines and be limited to an aggregate nominal value equal to (i) approximately 33% with regard to paragraph 7.1 of Resolution 7, and (ii) approximately 66% in relation to paragraph 7.2 of Resolution 7.

Accordingly, the maximum number of new ordinary shares which may be allotted pursuant to (a) paragraph 7.1 should be equal to an aggregate nominal value of GBP369,746 (not GBP396,746 as currently stated), and (b) paragraph 7.2 should be equal to an aggregate nominal value of GBP739,492 (not GBP793,492 as currently stated). A procedural resolution to approve such corrected Resolution 7 will be proposed at the AGM. A copy of the corrected Notice is available to view in the "Investor Relations" section of RUA's website at . The corrected Notice is also available for inspection at RUA's registered office (c/o Davidson Chalmers Stewart LLP, 163 Bath Street, Glasgow, G2 4SQ, UK). As these were clerical errors, no new Notice is required to be sent out to shareholders.

If shareholders have any questions in connection with the proposed business of the AGM, or the contents of this communication, they should email RUA's Company Secretary , Kate Full, at

For further information contact:

RUA Life Sciences

Bill Brown, Chairman Tel: +44 (0) 77 3071 8296

Shore Capital (Nominated Adviser and Joint Broker)

   Tom Griffiths/David Coaten                                                 Tel: +44 (0)20 7408 4080 
   Cenkos Securities plc (Joint Broker)                                 Tel: +44 (0) 20 7397 8900 

Russell Cook/Max Gould (Corporate Finance)

Michael Johnson (Sales)

About RUA Life Sciences

The RUA Life Sciences group was created in April 2020 when RUA Life Sciences Plc (formerly known as AorTech International Plc) acquired RUA Medical Devices Limited to create a fully formed medical device business. RUA Life Sciences is the holding company of the Group's four trading businesses, each exploiting the Group's patented polymer technology.

Our vision is to improve the lives of millions of patients by enabling medical devices with Elast-Eon (TM) , the world's leading long-term implantable polyurethane.

Whether it is licensing Elast-Eon (TM) , manufacturing a device or component, or developing next generation medical devices, a RUA Life Sciences business is pursuing our vision.

Elast-Eon(TM)'s biostability is comparable to silicone while exhibiting excellent mechanical, blood contacting and flex-fatigue properties. These polymers can be processed using conventional thermoplastic extrusion and moulding techniques. With over 7 million implants and 14 years of successful clinical use, RUA's polymers are proven in long-term life enabling applications.

The Group's four business units are:

 RUA Medical        End-to-end contract developer and manufacturer 
  :                  of medical devices and implantable fabric 
 RUA Biomaterials   Licensor of Elast-Eon (TM) polymers to the 
  :                  medical device industry. 
 RUA Vascular:      Development of large bore polymer sealed grafts 
                     and soft tissue patches. 
 RUA Structural     Development of tri leaflet polymeric heart 
  Heart :            valves. 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.



(END) Dow Jones Newswires

August 13, 2021 09:43 ET (13:43 GMT)

1 Year Rua Life Sciences Chart

1 Year Rua Life Sciences Chart

1 Month Rua Life Sciences Chart

1 Month Rua Life Sciences Chart
ADVFN Advertorial
Your Recent History
Rua Life S..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20220525 15:49:04